COMMUNIQUÉS West-GlobeNewswire

Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS

24/01/2018 - 22:06

Investor news Orphazyme A/S No. 01/2018 Copenhagen, January 24, 2018 – Orphazyme A/S , a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, today announced [...]

Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock

24/01/2018 - 22:02

SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

24/01/2018 - 22:01

Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights for LUXTURNA(TM) ( [...]

Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review

24/01/2018 - 22:01

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]

Albireo Announces Proposed Public Offering of Common Stock

24/01/2018 - 22:01

BOSTON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an [...]

ConforMIS Announces Proposed Public Offering of Common Stock

24/01/2018 - 22:01

BILLERICA, Mass., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]

Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers

24/01/2018 - 22:01

Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response One of Two Evaluable Patients with Recurrent, [...]

Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

24/01/2018 - 22:00

Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial rights for LUXTURNA™ ( [...]

Aviragen Therapeutics Issues Letter to Stockholders

24/01/2018 - 20:55

Reiterates Benefits of Proposed Merger with Vaxart Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. ( [...]

Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting

24/01/2018 - 18:30

MONTPELLIER, France, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sensorion ( FR 0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases , today announces that it will present five posters at [...]

Procured Health Expands Focus, Becomes Lumere

24/01/2018 - 18:02

CHICAGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- To better reflect its expanded focus, Procured Health, the leading provider of data-driven analytics, evidence and expert guidance to help health systems cut costs and reduce [...]

Solon Eiendom ASA : Endringer i opsjoner for ledende ansatte

24/01/2018 - 16:43

Solon Eiendom ASA - Endringer i opsjoner for ledende ansatte (Oslo, Norge, 24. januar 2018) Styret i Solon Eiendom ASA (" Solon" eller " Selskapet" ) har vedtatt en endring av vilkårene for opsjoner tildelt CEO, Andreas [...]

Solon Eiendom ASA : Amendments in options for executive management

24/01/2018 - 16:41

(Oslo, Norway, 24 January 2018) The board of directors of Solon Eiendom ASA (" Solon " or the " Company ") has resolved an amendment to the terms for options allocated to its CEO, Andreas Martinussen and CFO, Scott [...]

Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation

24/01/2018 - 16:25

ORION CORPORATION STOCK EXCHANGE RELEASE 24 JANUARY 2018 at 17.25 P.M. EET Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation The Nomination [...]

BioStem Technologies Inc. Announces New Board Member, Dr. Jennie Sandqvist

24/01/2018 - 16:05

Pompano Beach, FL, Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”) announced today that Dr. Jennie Sandqvist has joined the Company’s Board of Directors and Audit [...]

Immuron to Receive $2.16M R&D Tax Concession Refund

24/01/2018 - 15:30

Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ: IMRN ) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax [...]

Lexington Recieves Approval to Commence Clinical Study

24/01/2018 - 15:00

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce its [...]

Aterica Licenses mMed Patent Portfolio to Expand Application of its Digital Health Platform and Advance its Digital Health Initiatives for Individuals and Families

24/01/2018 - 15:00

WATERLOO, Ontario, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Aterica Inc. has entered into an agreement with New Directions Technology Consulting, LLC ( NDTC ) as the exclusive licensee of the mMed Patent Portfolio . This [...]

MRI Interventions Recognizes FDA Clearance of Voyager’s Investigational New Drug Application for VY-AADC Allowing its Pivotal Program to Begin for Advanced Parkinson’s Disease

24/01/2018 - 15:00

IRVINE, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today commented on Voyager Therapeutics’ announcement of FDA clearance of its Investigational New Drug (IND) application for VY-AADC [...]